Mission Statement, Vision, & Core Values (2026) of Sino Biopharmaceutical Limited.

Discover how Sino Biopharmaceutical Limited (1177.HK), founded in 2000, channels its declared mission of 'Science for a healthier world' into tangible outcomes across research, manufacturing and global expansion-operating major sites in Beijing, Shanghai, Nanjing, Lianyungang and Qingdao while ranking 39th globally and 2nd in China among the Top 50 Global Pharmaceutical Enterprises; with 2024 revenue at RMB28,866 million and R&D investment of about RMB2.58 billion in H1 2024 (roughly 16.2% of revenue), the company's vision to become a leading global innovator is anchored by core values-Integrity, Foresight, Innovation, Commitment, Efficiency and Collaboration-that steer its focus on oncology, hepatology, respiratory and surgical therapeutics and invite a closer look at the strategies driving its sustained growth and patient-centered breakthroughs.

Sino Biopharmaceutical Limited (1177.HK) - Intro

• Sino Biopharmaceutical Limited (1177.HK) is a Hong Kong-listed integrated pharmaceutical group focused on R&D, manufacturing and commercialization of innovative biologics and chemical drugs.
• Founded in 2000, the company's therapeutic portfolio emphasizes oncology, hepatology, respiratory diseases and surgery/analgesia.
• Manufacturing footprint spans multiple sites across China, supporting domestic supply and international export capacity.

• To discover, develop and deliver innovative and affordable medicines that address major unmet medical needs in China and globally.
• To drive sustainable growth through scientific excellence, quality manufacturing and patient-centric commercialization.

• To be a global leader in pharmaceutical innovation from China, continuously advancing therapeutic options and improving patient outcomes worldwide.

• Innovation - sustained investment in R&D to expand first-in-class and best-in-class pipelines.
• Quality - adherence to GMP standards across multiple manufacturing sites to ensure product safety and efficacy.
• Integrity - ethical conduct in clinical development, commercial practice and corporate governance.
• Patient Focus - prioritizing access, affordability and meaningful clinical benefits.

• Accelerate late-stage development and regulatory approvals for oncology and hepatology candidates.
• Expand biologics manufacturing capacity to meet increasing market demand.
• Increase international partnerships and out-licensing to broaden global reach.

• Key manufacturing sites: Beijing, Shanghai, Nanjing, Lianyungang, Qingdao.
• Integration of biologics and chemical drug production to support pipeline-to-market scale-up.

• Consistently ranked among the Top 50 global pharmaceutical companies for seven consecutive years, most recently 39th globally and 2nd in China.
• Reputation anchored by a balanced portfolio of biologics and small-molecule therapies and expanding manufacturing capacity.

Sino Biopharmaceutical Limited (1177.HK) - Overview

Sino Biopharmaceutical Limited (1177.HK) states its mission as 'Science for a healthier world,' committing the company to accelerate R&D innovation, leverage advanced technologies, and deliver diversified, high-quality, affordable treatment solutions worldwide. The mission prioritizes improving patient quality of life and dignity, tackling unmet needs in oncology, hepatology, and respiratory diseases, and aligning with strategic pillars of comprehensive innovation, internationalization, organizational integration, and digitalization.

• Core mission focus: accelerate R&D to address unmet medical needs in oncology, hepatology, respiratory and other major therapeutic areas.
• Patient-centric objective: improve quality of life and preserve dignity through accessible therapies.
• Strategic alignment: innovation-led growth, international expansion, internal integration, and digital transformation.

Key measurable commitments and operational indicators (selected):

• Therapeutic focus areas with active pipelines: oncology (targeted therapies, immuno-oncology), hepatology (anti-viral and liver disease therapeutics), respiratory (inhaled biologics, COPD/asthma agents).
• Internationalization milestones: registration filings and commercial launches in multiple APAC markets and selective collaborations in Europe and North America.
• Digital & organizational initiatives: centralized R&D platforms, digital manufacturing upgrades, and integrated commercial systems to improve time-to-market and cost-effectiveness.

Strategic R&D priorities directly supporting the mission:

• Invest in biologics and small-molecule pipelines that address high-burden diseases and unmet medical needs.
• Scale manufacturing capacity to improve affordability and supply security for critical therapies.
• Forge global partnerships and out-licensing to accelerate patient access outside Greater China.
• Deploy digital tools for clinical development, regulatory submissions, and real-world evidence generation.

For financial context and investor-focused analysis related to how these mission-driven investments impact corporate health and shareholder value, see: Breaking Down Sino Biopharmaceutical Limited Financial Health: Key Insights for Investors

Sino Biopharmaceutical Limited (1177.HK) - Mission Statement

• Global leadership ambition: expand presence across Greater China, Asia-Pacific, Europe and selected emerging markets through licensing, co-development and M&A.
• Innovation-first approach: prioritize first-in-class and best-in-class candidates, accelerating clinical development pipelines and leveraging biotechnology platforms.
• Patient-centric outcomes: align regulatory, manufacturing and post-market surveillance capabilities to improve efficacy, safety and access.

• Research & Development: sustain double-digit annual growth in R&D headcount and pipeline assets; focus on phase II/III transitions and biologics/ADC technologies.
• Commercial Execution: grow domestic market share in core therapeutic areas while launching 3-5 international registration programs within a 3-5 year horizon.
• Manufacturing & Quality: expand GMP capacity to support biologics volume increases and ensure international regulatory compliance (EMA/US FDA-ready facilities).
• Partnerships & Licensing: target strategic alliances to co-develop 6-8 programs and out-license select assets to accelerate global reach.
• Patient Access & CSR: implement tiered pricing, patient-assistance programs and expand access in lower-income regions.

• Scientific Rigor - evidence-driven decisions and robust clinical development.
• Patient First - safety, access and real-world outcomes guide prioritization.
• Integrity & Compliance - adherence to global regulatory and ethical standards.
• Collaboration - open innovation with academia, biotech and pharma partners.
• Continuous Improvement - operational excellence across manufacturing, supply chain and commercial functions.

• Pipeline acceleration: allocate increased capex and partnerships to move at least 4 assets into pivotal trials annually.
• Global registration strategy: pursue simultaneous submissions in China, EMA and select APAC markets for lead assets.
• Manufacturing scale-up: invest in biologics fill/finish and ADC manufacturing to reduce COGS and support launch volumes.
• Access programs: expand patient-assistance reach to tens of thousands of patients across core emerging markets within 2 years.

Sino Biopharmaceutical Limited (1177.HK) - Vision Statement

• Integrity - honesty, transparency and ethical decision‑making in all business activities to build and retain stakeholder trust.
• Foresight - anticipating scientific, regulatory and market trends to adapt strategy and capture emerging opportunities.
• Innovation - sustained R&D investment to expand a diversified pipeline of small molecules, biologics and specialty therapeutics.
• Commitment - focused on improving patient outcomes through quality medicines, access programs and clinical development.
• Efficiency - optimising manufacturing, supply chain and commercial operations to deliver products reliably and cost‑effectively.
• Collaboration - cross‑functional teamwork and external partnerships (academia, biotech, distributors) to accelerate development and market reach.

• Pipeline expansion: progressing clinical assets in oncology, cardiovascular, metabolic and immunology indications.
• R&D scale-up: increasing internal discovery and external licensing to balance in‑house platforms with collaborations.
• Global footprint: widening registration and distribution across Greater China, Asia, and selective Western markets.
• Sustainable operations: committing to ESG targets (product quality, environmental management and responsible governance).

• Integrity - clear compliance frameworks, external audits and public disclosure practices to reduce governance risk.
• Foresight - scenario planning and portfolio reprioritisation; percentage of sales from new products tracked annually.
• Innovation - pipeline KPIs: number of INDs, Phase II/III programs and regulatory submissions per year.
• Commitment - patient access metrics: treatment program reach, volume of donated medicines and post‑market safety reporting rates.
• Efficiency - OEE improvements, cost‑per‑dose reductions and shortened time‑to‑market for key launches.
• Collaboration - proportion of projects delivered via partnerships/joint ventures and co‑development agreements.

• Steady R&D spending as a percent of revenue to underpin long‑term pipeline growth.
• Portfolio diversification-balancing mature marketed brands with high‑potential clinical assets to stabilise revenue and drive future upside.
• Active business development: licensing in novel compounds and out‑licensing regional rights to accelerate global adoption.